The Journal of Urology
Volume 182, Issue 1 , Pages 125-132 , July 2009

Personalized Prediction of Tumor Response and Cancer Progression on Prostate Needle Biopsy

  • Michael J. Donovan

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Corresponding Author InformationCorrespondence: Aureon Laboratories, Inc., 28 Wells Ave., Yonkers, New York 10701 (telephone: 914-377-4037; FAX: 914-377-4001)
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Faisal M. Khan

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Gerardo Fernandez

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Ricardo Mesa-Tejada

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Yonkers and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Marina Sapir

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Valentina Bayer Zubek

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Douglas Powell

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Stephen Fogarasi

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Yevgen Vengrenyuk

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Mikhail Teverovskiy

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Mark R. Segal

      Affiliations

    • Center for Bioinformatics and Molecular Biostatistics, University of California-San Francisco, San Francisco, California
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • R. Jeffrey Karnes

      Affiliations

    • Mayo Clinic, Rochester, Minnesota
    • ,
  • Thomas A. Gaffey

      Affiliations

    • Mayo Clinic, Rochester, Minnesota
    • ,
  • Christer Busch

      Affiliations

    • University Hospital at Uppsala, Uppsala, Sweden
    • ,
  • Michael Haggman

      Affiliations

    • University Hospital at Uppsala, Uppsala, Sweden
    • ,
  • Peter Hlavcak

      Affiliations

    • University Hospital at Uppsala, Uppsala, Sweden
    • ,
  • Stephen J. Freedland

      Affiliations

    • Durham Veterans Affairs and Duke University Medical Center, Durham, North Carolina
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Robin T. Vollmer

      Affiliations

    • Durham Veterans Affairs and Duke University Medical Center, Durham, North Carolina
    • ,
  • Peter Albertsen

      Affiliations

    • University of Connecticut Health Science Center, Farmington, Connecticut
    • Financial interest and/or other relationship with Sanofi, Bristol Meyers, Galaxo and Blue Cross Blue Shield.
    • ,
  • Jose Costa

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Yale University School of Medicine, New Haven, Connecticut
    • Financial interest and/or other relationship with Aureon Laboratories.
    • ,
  • Carlos Cordon-Cardo

      Affiliations

    • Aureon Laboratories, Inc., New York, New York
    • Yonkers and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York
    • Financial interest and/or other relationship with Aureon Laboratories.

Received 18 December 2008

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71
  2. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781
  3. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977
  4. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol. 2006;7:355
  5. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008;112:1650
  6. Albertsen PC, Hanley JA, Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095
  7. Telesca D, Etzioni R, Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics. 2008;64:10
  8. Barry MJ, Kaufman DS, Wu CL. Case 15-2008: a 55 year-old-man with an elevated prostate-specific antigen level and early-stage prostate cancer. N Engl J Med. 2008;358:2161
  9. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095
  10. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Dotan ZA, Fearn PA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715
  11. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433
  12. Cordon-Cardo C, Kotsianti A, Verbel DA, Teverovsky M, Capodieci P, Hamann S, et al. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest. 2007;117:1876
  13. Donovan MJ, Hamann S, Clayton M, Khan FM, Sapir M, Bayer-Zubek V, et al. A systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol. 2008;26:3923
  14. van Diest PJ, Fleege JC, Baak JP. Syntactic structure analysis in invasive breast cancer: analysis of reproducibility, biologic background, and prognostic value. Hum Pathol. 1992;23:876
  15. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766
  16. Bianco FJ. Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era. Urol Oncol Semin Orig Invest. 2008;26:408
  17. Smaletz O, Scher HI, Small EJ, Verbel D, McMillan A, Regan K, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20:3972
  18. Tu YK, Gunnell D, Gilthorpe MS. Simpson's paradox, Lord's paradox, and Suppression Effects are the same phenomenon—the reversal paradox. Emerg Themes Epidemiol. 2008;5:2
  19. Gonzalgo ML, Bastian PJ, Mangold LA, Trock BJ, Epstein JI, Walsh PC, et al. Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology. 2006;67:115
  20. Grober ED, Tsihlias J, Jewett MA, Sweet JM, Evans AJ, Trachtenberg J, et al. Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors. Can J Urol. 2004;11:2157
  21. Muntener M, Epstein JI, Hernandez DJ, Gonzalgo ML, Mangold L, Humpreys E, et al. Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol. 2008;53:767
  22. Bubendorf L, Tapia C, Gasser TC, Casella R, Grunder B, Moch H, et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol. 1998;29:949
  23. Mucci NR, Rubin MA, Strawderman MS, Montie JE, Smith DC, Pienta KJ. Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. J Natl Cancer Inst. 2000;92:1941
  24. Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92–02. J Clin Oncol. 2004;22:2133
  25. Aaltomaa S, Karja V, Lipponen P, Isotalo T, Kankkunen JP, Talja M, et al. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res. 2006;26:4873
  26. Shimizu Y, Segawa T, Inoue T, Shiraishi T, Yoshida T, Toda Y, et al. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int. 2007;100:685
  27. Wang Y, Kreisberg JI, Ghosh PM. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets. 2007;7:591
  28. McCall P, Gemmell LK, Mukherjee R, Bartlett J, Edwards J. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer. 2008;98:1094
  29. Khatami A, Pihl CG, Norrby K, Hugosson J, Damber JE. Is tumor vascularity in prostate core biopsies a predictor of PSA recurrence after radical prostatectomy?. Acta Oncol. 2005;44:362

 Study received Durham Veterans Affairs Medical Center, Mayo Clinic, University of Connecticut Health Science Center, University of Graz and University Hospital at Uppsala institutional review board approval.

 Supported by an Aureon Laboratories sponsored research agreement.

 Supplementary material for this article can be obtained at jason.alter@aureon.com.

 For another article on a related topic see page 317.

PII: S0022-5347(09)00570-9

doi: 10.1016/j.juro.2009.02.135

The Journal of Urology
Volume 182, Issue 1 , Pages 125-132 , July 2009

Article Tools

* Image Usage & Resolution